Ca-AKG vs NMN: mechanisms and human evidence compared

Ca-AKG and NMN are not two versions of the same longevity strategy. Ca-AKG is an alpha-ketoglutarate salt tied to central metabolism, AKG-dependent enzymes and several preclinical aging pathways. NMN is an NAD+ precursor with a much larger randomized human target-engagement literature.

The strongest difference in 2026 is evidence maturity: NMN has clearer human evidence that it changes its intended biochemical target, while Ca-AKG's most prominent human aging signal remains observational. Neither has shown that it extends human lifespan.

Ca-AKG vs NMN at a glance

Question	Ca-AKG	NMN
Core biology	TCA-cycle metabolite; AKG-dependent dioxygenase cofactor; nutrient/immune signaling	NAD+ biosynthetic precursor
Human target engagement	Oral metabolic activity shown; aging-pathway target engagement less directly characterized	Repeated randomized evidence that supplementation raises blood NAD+ or related metabolites
Human aging signal	Observational DNA-methylation-age association for delayed-release product	Multiple small RCTs across metabolic, physical and vascular outcomes; effects inconsistent
Hard longevity outcomes	None in humans	None in humans
Mouse lifespan evidence	Mixed	Positive aging-phenotype data exist, but not equivalent to human lifespan evidence

What does NMN actually do in humans?

NMN is a direct intermediate in NAD+ biosynthesis. Human supplementation studies repeatedly show that it can alter circulating NAD+ metabolism.

A well-controlled 2023 trial of the microcrystalline NMN formulation MIB-626 found dose-dependent increases in circulating NAD+ and related metabolites in middle-aged and older adults [1].

That is strong target-engagement evidence: the supplement changes the biochemical system it is intended to change.

Target engagement is not the same as clinical benefit.

Does NAD+ actually decline with age in humans?

The simple claim that blood NAD+ universally declines with age is no longer defensible.

A 2026 study using seven independent human cohorts found whole-blood NAD+ levels remarkably stable with age and across lifestyle interventions [2].

That does not mean NAD biology is irrelevant to aging. Tissue-specific NAD+ can behave differently from whole blood, and supplementation can still increase NAD-related metabolites.

It does mean “everyone is NAD-deficient because they are older” is too broad a rationale for NMN.

What does the 2026 NMN meta-analysis say?

A 2026 systematic review and meta-analysis included 15 randomized trials of NMN or closely related oral preparations [3].

Across doses of roughly 250–2,000 mg/day and durations up to 24 weeks, NMN was generally well tolerated and did not increase overall or serious adverse events in the pooled safety analyses.

But broad metabolic efficacy was limited. The meta-analysis found no significant overall effect on body weight, BMI, fasting glucose, HbA1c, lipid profiles or systolic blood pressure. Diastolic blood pressure showed a small reduction, while HOMA-IR had a non-significant favorable trend.

That is a useful 2026 summary: NMN changes NAD biology more consistently than it changes broad clinical-metabolic outcomes.

Are there any positive human NMN efficacy signals?

Yes, but they are endpoint- and population-specific.

A 2021 randomized trial in postmenopausal women with prediabetes found improved skeletal-muscle insulin sensitivity after NMN supplementation [4].

Other trials have reported signals in walking speed, sleep, aerobic capacity or physical performance in selected populations. The overall literature is heterogeneous, which is why pooled analyses do not support a simple “NMN improves metabolism” conclusion.

What is Ca-AKG's comparable human evidence?

Ca-AKG's most visible modern aging evidence is the Rejuvant biological-age literature.

The 2026 observational cohort found delayed-release AKG users had an average Age Residual about 1.8 years lower than non-users in cross-sectional analysis, while plain non-delayed AKG showed a smaller non-significant association [5].

The adjusted longitudinal delayed-release result was not significant after controlling for baseline Age Residual and regression to the mean.

ABLE is the key randomized Ca-AKG trial, using 1 g/day sustained-release Ca-AKG versus placebo, but the audited corpus contains the protocol and recruitment analysis rather than efficacy outcomes [6].

Which has stronger human evidence?

That depends on what “stronger” means.

For biochemical target engagement: NMN has the clearer human case because multiple randomized studies show changes in NAD+ metabolism.

For a direct human biological-age association: Ca-AKG has the Rejuvant/Pabis observational signal, but it is not randomized causal evidence.

For broad clinical outcomes: neither supplement has established a major anti-aging clinical benefit, and NMN's larger trial literature is mixed.

For human lifespan or disease prevention: neither has evidence.

What does the mouse evidence look like?

Ca-AKG's mouse lifespan evidence is now explicitly mixed.

The 2020 Shahmirzadi study reported significant female lifespan extension and lower frailty burden in C57BL/6 mice [7].

Two later NIA Interventions Testing Program studies in genetically heterogeneous UM-HET3 mice did not reproduce lifespan extension [8] [9].

NMN has extensive preclinical aging research, but positive mouse physiology does not answer the human longevity question either.

What about exercise?

This is another place where “more pathway activity” is not automatically better.

A 2026 randomized crossover study found NMN altered the inflammatory response to blood-flow-restricted exercise in human skeletal muscle [10].

The study provides genuine human tissue-level mechanistic evidence, but its results are specific to one exercise model and should not be generalized into “NMN improves” or “NMN harms” training adaptation overall.

Ca-AKG has much less direct human muscle-biopsy evidence; its muscle and exercise case remains mostly preclinical plus limited mixed-salt human data.

Can Ca-AKG and NMN be taken together?

No published human trial has established the efficacy or safety of the combination as a longevity intervention.

The mechanisms are distinct enough that researchers could reasonably test them together. That does not establish synergy.

If both are used, the evidence still comes from two separate ingredient literatures. See Ca-AKG stacking.

Which one is “better”?

There is no evidence-based universal winner because the compounds answer different questions.

If the question is “which supplement more reliably changes a measured human biochemical target?”, NMN has stronger evidence for NAD+ target engagement.

If the question is “which has shown human lifespan extension, disease prevention or a validated anti-aging effect?”, neither has.

If the question is “which has a human biological-age signal?”, delayed-release Ca-AKG has an observational association, while NMN's evidence is centered more on NAD metabolism and specific physiological outcomes.

Bottom line

NMN has the larger randomized human evidence base and clearer biochemical target engagement. Its clinical outcome effects, however, are inconsistent, and a 2026 meta-analysis found no broad metabolic benefit despite favorable short-term tolerability.

Ca-AKG has a smaller human aging literature, an observational delayed-release biological-age signal, decades of non-longevity exposure data and a mixed mouse lifespan record.

Neither supplement has demonstrated that it slows human aging, prevents age-related disease or extends human lifespan.

The comparison is therefore best understood as two different biological strategies with different evidence profiles—not a contest with a proven winner.